Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
05/2003
05/07/2003CN1416339A IL-8 receptor antagonsts
05/07/2003CN1415310A Nano selenium of chitin and its preparation method
05/07/2003CN1415309A Nano selenium of Melatonin and its preparation method
05/07/2003CN1415308A Nano selenium of amino acid and its preparation method
05/07/2003CN1415304A Anticancer adjuvant containing 20 (S)-ginsenoside Rh2 as effective content and application thereof
05/07/2003CN1415301A Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application
05/07/2003CN1415293A Alkaloid of matrine category utilized for mainline and its preparation method
05/07/2003CN1107681C Compound of polypeptide as antigen of hepatitis B virus and heat shock protein and its application
05/07/2003CN1107680C Australian solanic amine salt hydrochloride its prodn. method and medical application
05/07/2003CN1107678C Highly lipophilic camptothcin derivatives, its prepn. method and uses
05/07/2003CN1107677C Camptothecin derivatives and use thereof as antimutor agents
05/07/2003CN1107669C 维生素d类似物 Vitamin d analogues
05/07/2003CN1107500C Oral rapamycin formulations
05/06/2003US6559282 Induction of antibodies against leutenizing hormone releasing hormone in mammals; obtain mammal, administer modulator, monitor immune response, evaluate for prevention of infections
05/06/2003US6559280 Controlling protein levels in eucaryotic organisms
05/06/2003US6559183 Nano-emulsion of 5-aminolevulinic acid
05/06/2003US6559181 A method to treat endometrial carcinoma, prostate cancer, or prostate hyperplasia comprising administering to a patient in need of such treatment an effective dose of a 3,4-Diphenyl-bicyclo(4.3.0)nonyl compound of formula I
05/06/2003US6559173 organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
05/06/2003US6559168 Thiazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/06/2003US6559161 Cytotoxic pyrido[2,3,4-ki]acridine derivatives, their preparation and their therapeutic use
05/06/2003US6559160 These compounds and compositions bind to the CXCR3 chemokine receptor and are useful for treating diseases and conditions responsive to the modulation of CXCR3 activity, such as multiple sclerosis, rheumatoid arthritis, psoriasis, cancer,
05/06/2003US6559152 6-substituted pyrazolo[3,4-d]pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
05/06/2003US6559147 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example
05/06/2003US6559142 Tricyclic substituted cyclic sulfonamides compound is useful for treating heart disease, multiple sclerosis, arthritis, atherosclerosis, and osteoporosis
05/06/2003US6559139 Combination chemotherapy
05/06/2003US6559126 Peptides blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
05/06/2003US6558951 Induction of maturation of dendritic cells; obtain immature dendritic cells, incubate with modulator, monitor development and recover dendritic cells
05/06/2003US6558925 Stem cell inhibitor
05/06/2003US6558918 Nucleic acid that encode a cell growth regulatory protein
05/06/2003US6558912 Screening for modulators of apoptosis; obtain cells containing apoptosis polypeptide, incubate with binding protein, expose to modulator, monitor concentration of bound protein in presence of modulator, compare to control
05/06/2003US6558675 Mutant human hepatitis B viral strain and uses thereof
05/06/2003US6558672 Methods of making recombinant disulfide-stabilized polypeptide fragments having binding specificity
05/06/2003US6558662 Treatment of hematologic disorders
05/06/2003CA2126691C Gapped 2' modified oligonucleotides
05/06/2003CA2082160C Humanised and chimeric monoclonal antibodies
05/02/2003EP1306436A1 P53-dependent novel apoptosis-associated protein and method of screening apoptosis controlling agent
05/02/2003EP1306431A1 Tumor antigen
05/02/2003EP1306427A1 Method of proliferating natural killer cells
05/02/2003EP1306375A1 Salts of benzimidazole compound and use thereof
05/02/2003EP1306095A2 Methods and compositions for targeting the vasculature of solid tumors
05/02/2003EP1305635A2 Methods to identify compounds that modulate rage
05/02/2003EP1305434A2 A human disintegrin protein
05/02/2003EP1305426A2 25324, 50287, 28899, 47007 and 42967, transferase family members, and uses therefor
05/02/2003EP1305425A2 Drug metabolizing enzymes
05/02/2003EP1305419A2 Isolated nucleic acid molecules which encode t cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
05/02/2003EP1305414A2 Modified cea and uses thereof
05/02/2003EP1305404A2 Protein phosphatases
05/02/2003EP1305342A2 Human kininogen d5 domain polypeptides and their use
05/02/2003EP1305340A2 Sequences for integrin alpha-8
05/02/2003EP1305336A2 Therapeutic anti-melanoma compounds
05/02/2003EP1305332A2 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid
05/02/2003EP1305322A2 Derivatives of branched-chain lipophilic molecules and uses thereof
05/02/2003EP1305317A1 Dihydroporphyrin derivatives and their uses
05/02/2003EP1305316A2 Azabicyclic derivatives and their therapeutic use
05/02/2003EP1305313A1 Fused heterocyclic derivatives as phosphodiesterase inhibitors
05/02/2003EP1305306A2 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
05/02/2003EP1305304A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor
05/02/2003EP1305303A1 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE
05/02/2003EP1305299A1 Cyclic polyamine compounds for cancer therapy
05/02/2003EP1305295A1 Imidazole derivatives
05/02/2003EP1305294A2 Imidazolyl derivatives
05/02/2003EP1305293A1 Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase
05/02/2003EP1305290A1 Novel heteroaryl derivatives and the use thereof as pharmaceuticals
05/02/2003EP1305289A2 Novel heteroaryl derivatives and use thereof as anti-tumour agents
05/02/2003EP1305285A1 N-substituted indoles useful in the treatment of diabetes
05/02/2003EP1305274A2 Novel c-4 substituted retinoids
05/02/2003EP1305051A2 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
05/02/2003EP1305045A1 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
05/02/2003EP1305041A1 Medicament for the immunotherapy of malignant tumours
05/02/2003EP1305030A1 USE OF 2$g(a)-METHYL-19-NOR-20(S)-1$g(a),25-DIHYDROXYVITAMIN D3 TO INCREASE BONE STRENGTH
05/02/2003EP1305027A2 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer
05/02/2003EP1305026A2 Barbituric acid analogs as therapeutic agents
05/02/2003EP1305024A1 Method for treating fibrotic diseases or other indications ic
05/02/2003EP1305023A1 Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
05/02/2003EP1305019A2 Immunomodulatory compounds
05/02/2003EP1305015A1 Substituted styryl benzylsulfones for treating proliferative disorders
05/02/2003EP1305006A2 Dispersions for formulating slightly or poorly soluble active ingredients
05/02/2003EP1305004A1 Embolization using carbon coated particles
05/02/2003EP1304921A2 Transgenic mice containing targeted gene disruptions
05/02/2003EP1223966B1 Use of gdnf for treating corneal defects
05/02/2003EP1221939A4 Ortho ester lipids
05/02/2003EP1189611A4 Cancer therapy
05/02/2003EP1185516B1 Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
05/02/2003EP1119351B1 Use of catechol derivatives as proteinase inhibitors
05/02/2003EP1094839B1 Farnesyl protein transferase inhibitors with (in vivo) radiosensitizing properties
05/02/2003EP1070058B1 (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides
05/02/2003EP1056704B1 Antitumor agents
05/02/2003EP1045846B1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
05/02/2003EP1037886B1 Triazine angiogenesis inhibitors
05/02/2003EP1036167B1 Nuclear targeting by means of streptococcal protein h
05/02/2003EP1025082B1 Novel vitamin d derivatives with cyclopropyl rings in the lateral chains, a method and intermediate products for the production thereof and the utilization thereof for producing medicaments
05/02/2003EP1021448B1 TRICYCLIC COMPOUNDS HAVING ACTIVITY AS Ras-FPT INHIBITORS
05/02/2003EP1015423B1 1,3-dihydroxy-20,20-dialkyl-vitamin d 3? analogs
05/02/2003EP0948544B1 Monovalent antibody fragments
05/02/2003EP0929578B1 HUMAN ANTIBODIES THAT BIND HUMAN TNFalpha
05/02/2003EP0901482B1 Benzofuran carboxamides and their therapeutic use
05/02/2003EP0854874B1 Macrocyclic lactone compounds and their production process
05/02/2003EP0811006B1 Benzopyran-containing compounds and method for their use
05/02/2003EP0674710B1 Peptides with broad neoplastic specificity
05/02/2003CA2411015A1 5-(alkylidene-cycloalkyl)- and 5-(alkylidene-heterocyclyl)-pyrazoles
1 ... 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 ... 2211